​

Atai Life Sciences (ATAI) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ATAI Stock Forecast

Atai Life Sciences stock forecast is as follows: an average price target of $6.00 (represents a 404.20% upside from ATAI’s last price of $1.19) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

ATAI Price Target

The average price target for Atai Life Sciences (ATAI) is $6.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 404.20% upside from ATAI's last price of $1.19.

ATAI Analyst Ratings

Buy

According to 3 Wall Street analysts, Atai Life Sciences's rating consensus is 'Buy'. The analyst rating breakdown for ATAI stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Atai Life Sciences Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 03, 2024Jason McCarthyMaxim Group$6.00$1.87220.86%404.20%

The latest Atai Life Sciences stock forecast, released on Apr 03, 2024 by Jason McCarthy from Maxim Group, set a price target of $6.00, which represents a 220.86% increase from the stock price at the time of the forecast ($1.87), and a 404.20% increase from ATAI last price ($1.19).

Atai Life Sciences Price Target by Period

1M3M12M
# Anlaysts--1
Avg Price Target--$6.00
Last Closing Price$1.19$1.19$1.19
Upside/Downside-100.00%-100.00%404.20%

In the current month, the average price target of Atai Life Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Atai Life Sciences's last price of $1.19. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Sep 03, 2024H.C. WainwrightBuyBuyHold
Aug 15, 2024Cowen & Co.BuyBuyHold
Jan 06, 2023EF HuttonBuyBuyHold

Atai Life Sciences's last stock rating was published by H.C. Wainwright on Sep 03, 2024. The company gave ATAI a "Buy" rating, the same as its previous rate.

Atai Life Sciences Financial Forecast

Atai Life Sciences Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23Dec 22Dec 21
Revenue--------$38.00K-
Avg Forecast$375.00K$33.59K$35.09K$36.66K$300.00K$40.00K$273.00K$187.60K$100.86K$-18.25K
High Forecast$375.00K$33.59K$35.09K$36.66K$300.00K$40.00K$273.00K$187.60K$100.86K$-18.25K
Low Forecast$375.00K$33.59K$35.09K$36.66K$300.00K$40.00K$273.00K$187.60K$100.86K$-18.25K
# Analysts1111311311
Surprise %--------0.38%-

Atai Life Sciences's average Quarter revenue forecast for Dec 23 based on 3 analysts is $187.60K, with a low forecast of $187.60K, and a high forecast of $187.60K. ATAI's average Quarter revenue forecast represents a 393.68% increase compared to the company's last Quarter revenue of $38.00K (Dec 22).

Atai Life Sciences EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23Dec 22Dec 21
# Analysts1111311311
EBITDA--------$-37.56M$-85.29M
Avg Forecast$-75.00K$-6.72K$-7.02K$-7.33K$-60.00K$-8.00K$-54.60K$-37.52K$-20.17K$3.65K
High Forecast$-75.00K$-6.72K$-7.02K$-7.33K$-60.00K$-8.00K$-54.60K$-37.52K$-20.17K$3.65K
Low Forecast$-75.00K$-6.72K$-7.02K$-7.33K$-60.00K$-8.00K$-54.60K$-37.52K$-20.17K$3.65K
Surprise %--------1862.33%-23373.80%

undefined analysts predict ATAI's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Atai Life Sciences's previous annual EBITDA (undefined) of $NaN.

Atai Life Sciences Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23Dec 22Dec 21
# Analysts1111311311
Net Income--------$-45.32M$-52.14M
Avg Forecast$-28.11M$-25.70M$-24.49M$-24.09M$-23.18M$-25.70M$-25.69M$-24.36M$-36.86M$-37.80M
High Forecast$-28.11M$-25.70M$-24.49M$-20.88M$-16.55M$-25.70M$-25.69M$-20.06M$-36.86M$-37.80M
Low Forecast$-28.11M$-25.70M$-24.49M$-27.31M$-28.14M$-25.70M$-25.69M$-27.23M$-36.86M$-37.80M
Surprise %--------1.23%1.38%

Atai Life Sciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ATAI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Atai Life Sciences SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23Dec 22Dec 21
# Analysts1111311311
SG&A--------$15.73M$25.88M
Avg Forecast$38.32M$3.43M$3.59M$3.75M$30.66M$4.09M$27.90M$19.17M$10.31M$-1.87M
High Forecast$38.32M$3.43M$3.59M$3.75M$30.66M$4.09M$27.90M$19.17M$10.31M$-1.87M
Low Forecast$38.32M$3.43M$3.59M$3.75M$30.66M$4.09M$27.90M$19.17M$10.31M$-1.87M
Surprise %--------1.53%-13.87%

Atai Life Sciences's average Quarter SG&A projection for Dec 23 is $19.17M, based on 3 Wall Street analysts, with a range of $19.17M to $19.17M. The forecast indicates a 21.90% rise compared to ATAI last annual SG&A of $15.73M (Dec 22).

Atai Life Sciences EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23Dec 22Dec 21
# Analysts1111311311
EPS--------$-0.29$-0.34
Avg Forecast$-0.17$-0.16$-0.15$-0.15$-0.14$-0.16$-0.16$-0.15$-0.23$-0.24
High Forecast$-0.17$-0.16$-0.15$-0.13$-0.10$-0.16$-0.16$-0.12$-0.23$-0.24
Low Forecast$-0.17$-0.16$-0.15$-0.17$-0.18$-0.16$-0.16$-0.17$-0.23$-0.24
Surprise %--------1.26%1.44%

According to undefined Wall Street analysts, Atai Life Sciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ATAI previous annual EPS of $NaN (undefined).

Atai Life Sciences Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
MOLNMolecular Partners$5.25$29.00452.38%Buy
ATAIAtai Life Sciences$1.32$6.00354.55%Buy
ITOSiTeos Therapeutics$7.69$33.50335.63%Buy
OPTOpthea$3.27$14.00328.13%Buy
GHRSGH Research$8.46$28.00230.97%Buy
MNMDMind Medicine (MindMed)$7.48$14.0087.17%Buy
EWTXEdgewise Therapeutics$30.17$46.2553.30%Buy

ATAI Forecast FAQ

Is Atai Life Sciences a good buy?

Yes, according to 3 Wall Street analysts, Atai Life Sciences (ATAI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of ATAI's total ratings.

What is ATAI's price target?

Atai Life Sciences (ATAI) average price target is $6 with a range of $6 to $6, implying a 404.20% from its last price of $1.19. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Atai Life Sciences stock go up soon?

According to Wall Street analysts' prediction for ATAI stock, the company can go up by 404.20% (from the last price of $1.19 to the average price target of $6), up by 404.20% based on the highest stock price target, and up by 404.20% based on the lowest stock price target.

Can Atai Life Sciences stock reach $2?

ATAI's average twelve months analyst stock price target of $6 supports the claim that Atai Life Sciences can reach $2 in the near future.

What are Atai Life Sciences's analysts' financial forecasts?

Atai Life Sciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $613K (high $613K, low $613K), average EBITDA is $-123K (high $-123K, low $-123K), average net income is $-74.57M (high $-67.947M, low $-79.536M), average SG&A $62.65M (high $62.65M, low $62.65M), and average EPS is $-0.464 (high $-0.423, low $-0.495). ATAI's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $480.33K (high $480.33K, low $480.33K), average EBITDA is $-96.063K (high $-96.063K, low $-96.063K), average net income is $-102M (high $-99.184M, low $-106M), average SG&A $49.09M (high $49.09M, low $49.09M), and average EPS is $-0.637 (high $-0.617, low $-0.657).

Did the ATAI's actual financial results beat the analysts' financial forecasts?

Based on Atai Life Sciences's last annual report (Dec 2022), the company's revenue was $233K, beating the average analysts forecast of $100.86K by 131.02%. Apple's EBITDA was $-144M, beating the average prediction of $-20.171K by 714158.09%. The company's net income was $-141M, beating the average estimation of $-36.861M by 283.63%. Apple's SG&A was $70.35M, beating the average forecast of $10.31M by 582.54%. Lastly, the company's EPS was $-0.91, beating the average prediction of $-0.229 by 296.53%. In terms of the last quarterly report (Dec 2022), Atai Life Sciences's revenue was $38K, missing the average analysts' forecast of $100.86K by -62.32%. The company's EBITDA was $-37.565M, beating the average prediction of $-20.171K by 186132.71%. Atai Life Sciences's net income was $-45.323M, beating the average estimation of $-36.861M by 22.96%. The company's SG&A was $15.73M, beating the average forecast of $10.31M by 52.58%. Lastly, the company's EPS was $-0.29, beating the average prediction of $-0.229 by 26.37%